Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal
Strategic angle: Neurocrine Biosciences is acquiring Soleno Therapeutics for $2.9 billion, gaining access to a treatment for a rare disease linked to insatiable hunger.
Neurocrine Biosciences has announced its acquisition of Soleno Therapeutics for a total consideration of $2.9 billion. This strategic move is aimed at expanding Neurocrine's therapeutic offerings.
Soleno Therapeutics brings to the table an approved medication targeting a rare disease characterized by insatiable hunger. This condition presents unique challenges in treatment and management.
The acquisition reflects a growing trend in the biotechnology sector where companies seek to enhance their capabilities through targeted acquisitions, particularly in niche therapeutic areas.